Healthtech firm Harrison.ai of Sydney, Australia, has announced that it is expanding its operations into the U.S., a move supported and accelerated by $112 million in Series C funding.
The funding round was led by Aware Super, ECP, and existing investors Horizons Ventures, Blackbird Ventures, and Alpha JWC Ventures. Australia's National Reconstruction Fund Corporation (NRFC), Ord Minnett, and Wollemi Capital Group participated as new investors.
The funding will also fuel the company’s production and continued growth in the U.K., the European Union, the Middle East, Africa, and the Asia-Pacific region, the firm said in a statement. It noted that it is establishing its North American presence in Boston, with a focus on building its U.S. operations and growing its customer base.
Harrison.ai diagnostic support technology uses AI to analyze CT scans, x-rays, and pathology slides, supporting clinicians in diagnosing medical conditions earlier and with better accuracy, improving clinical decision-making and patient outcomes.
Harrison.ai has raised more than $240 million in capital to date. It has also secured 12 U.S. Food and Drug Administration (FDA) clearances and received FDA breakthrough device designation and Medicare reimbursement through the New Technology Add-on Payment (NTAP) for one of its CT brain algorithms.
